Arcutis Biotherapeutics announced positive topline results from its phase 3 trial of roflumilast cream in adults and children aged 6 years and older with mild to moderate atopic dermatitis, according to a company press release.
“Itch reduction is particularly important in atopic dermatitis, being so prevalent and burdensome that the disease is often referred to as ‘the itch that rashes,’” Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis, told Healio. “We are happy to have shown the rapid onset of response in both efficacy and itch as early as week